Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 25:9:e08.
doi: 10.15420/cfr.2022.26. eCollection 2023.

Role of Imaging in Cardiomyopathies

Affiliations
Review

Role of Imaging in Cardiomyopathies

Vincenzo Castiglione et al. Card Fail Rev. .

Abstract

Imaging has a central role in the diagnosis, classification, and clinical management of cardiomyopathies. While echocardiography is the first-line technique, given its wide availability and safety, advanced imaging, including cardiovascular magnetic resonance (CMR), nuclear medicine and CT, is increasingly needed to refine the diagnosis or guide therapeutic decision-making. In selected cases, such as in transthyretin-related cardiac amyloidosis or in arrhythmogenic cardiomyopathy, the demonstration of histological features of the disease can be avoided when typical findings are observed at bone-tracer scintigraphy or CMR, respectively. Findings from imaging techniques should always be integrated with data from the clinical, electrocardiographic, biomarker, genetic and functional evaluation to pursue an individualised approach to patients with cardiomyopathy.

Keywords: Imaging; cardiac magnetic resonance; cardiomyopathies; echocardiography; nuclear medicine.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors have no conflicts of interest to declare.

Figures

Figure 1:
Figure 1:. Echocardiography in Cardiac Amyloidosis
Figure 2:
Figure 2:. Cardiac Magnetic Resonance in Dilated Cardiomyopathy Left Ventricular Dilation in a Patient with Dilated Cardiomyopathy
Figure 3:
Figure 3:. Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy Disproportionate Apical Hypertrophy in a Patient with Hypertrophic Cardiomyopathy
Figure 4:
Figure 4:. Cardiac Magnetic Resonance in Arrhythmogenic Cardiomyopathy Right Ventricular Arrhythmogenic Cardiomyopathy, Manifesting with Right Ventricular Free Wall Hypo/Akinesia
Figure 5:
Figure 5:. Nuclear Medicine in Cardiac Amyloidosis Scans from 18F-Florbetaben PET and from 99mTc-HDP Scintigraphy in a Patient with Light Chain Cardiac Amyloidosis

References

    1. Elliott P, Andersson B, Arbustini E et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270–6. doi: 10.1093/eurheartj/ehm342. - DOI - PubMed
    1. Garcia-Pavia P, Rapezzi C, Adler Y et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021;23:512–26. doi: 10.1002/ejhf.2140. - DOI - PubMed
    1. Casas G, Rodríguez-Palomares JF. Multimodality cardiac imaging in cardiomyopathies: from diagnosis to prognosis. J Clin Med. 2022;11:578. doi: 10.3390/jcm11030578. - DOI - PMC - PubMed
    1. Rankin K, Thampinathan B, Thavendiranathan P. Imaging-specific cardiomyopathies a practical guide. Heart Fail Clin. 2019;15:275–95. doi: 10.1016/j.hfc.2018.12.007. - DOI - PubMed
    1. Cardim N, Galderisi M, Edvardsen T et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging. 2015;16:280. doi: 10.1093/ehjci/jeu291. - DOI - PubMed